



**GOLDFINGER**  
COMMUNICATIONS

March 10, 2017

## **Therapix and Rafa signed a Memorandum of Understanding for the formation of a venture to research and develop a cannabinoid-based drug for treating toothaches and periodontal diseases**

**Therapix Biosciences (OTC: THXBY) (TASE: THXBY.TA)**, a pharma company specializing in the development of cannabinoid-based drugs, signed a non-binding Memorandum of Understandings (MOU) for a strategic cooperation with Rafa Laboratories Ltd., a leading pharmaceutical company (“**Rafa**”), for the formation of a venture to research and develop a drug for treating toothaches and various periodontal diseases. In the context of the venture, *inter alia*, a clinical proof-of-concept study will be conducted in respect of a drug based on Therapix’s licensed entourage technology, in combination with an approved cannabinoid drug and the PEA additive, while integrating a drug administration platform owned by a third party.

According to the MOU, Therapix and Rafa will invest seed capital in the venture in consideration for holdings therein, according to a ratio and percentage that were determined in the MOU. The venture will raise capital, as necessary for its activity, and will bear all of the expenses and payments related to the research and development of the drug, the performance of the clinical trials, and the manufacture and marketing of the drug.

Rafa will receive an exclusive right to manufacture the drug in the aforesaid indications in certain territories, and a right to offer supply of the drug in additional territories, as well as an exclusive right to market it in Israel.

### **About Therapix**

Therapix is an Israeli-based clinical-stage pharma company focused on the development and commercialization of cannabinoid drugs. The company is listed on the Tel Aviv Stock Exchange and traded over-the counter (OTC) in the United States. Therapix’s CEO is Dr. Elran Haber and its Chairman is Dr. Ascher Shmulewitz.

### **About Rafa**

Rafa is one of Israel’s leading pharmaceutical companies. The company specializes in marketing, manufacture and distribution of proprietary and generic formulations, prescription and over-the-counter medicines, as well as therapeutic products in various medical fields such as pain, gastroenterology, respiratory diseases and dermatology. One of Rafa’s fields of expertise is the manufacture of drugs for other companies, implementing the contract manufacturing method, and it offers a range of services under a one-stop-shop concept. Rafa has an advanced manufacturing facility approved for production in Israel, Europe and additional countries in the world.





**GOLDFINGER**  
COMMUNICATIONS

### **Forward Looking Statements**

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Because such statements deal with future events and are based on Therapix’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Therapix could differ materially from those described in or implied by the statements in this press release. For example, forward-looking statements include statements regarding collaboration with Rafa. In addition, historic results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Therapix Biosciences Ltd.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) and in subsequent filings with the SEC. Except as otherwise required by law, Therapix disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise

